Metabolism of 2',3'-dideoxy-2',3'-didehydro-β-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D(+) nucleoside analogs in vitro

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1799-1804

  Dutschman, Ginger E ^a   Bridges, Edward G ^a   Liu, Shwu Huey ^a   Gullen, Elizabeth ^a   Guo, Xin ^a   Kukhanova, Marina ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEHYDRO 2',3' DIDEOXYCYTIDINE; DIDANOSINE; FLUCYTOSINE DEOXYRIBOSIDE; NUCLEOSIDE ANALOG; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DEAMINATION; DNA SYNTHESIS INHIBITION; DNA TEMPLATE; DRUG EFFECT; DRUG METABOLISM; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0031836316     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1799     Document Type: Article

References (44)

1. Bridges, E. G., G. E. Dutschman, E. A. Gullen, and Y.-C. Cheng. 1996. Favorable interaction of β-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem. Pharmacol. 51:731-736.
2. Bridges, E. G., Z. L. Jiang, and Y. C. Cheng. 1997. Identification of a novel mitochondrial dNTP carrier and its interaction with anti-HIV nucleoside analogs. Proc. Am. Assoc. Cancer Res. 38:414.
3. Chang, C.-N., S.-L. Doong, J. H. Zhou, J. W. Beach, L. S. Jeong, C. K. Chu, C.-H. Tsai, D. C. Liotta, R. F. Schinazi, and Y.-C. Cheng. 1992. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 267:13938-13942.
4. Chang, C. N., V. Skalski, J. H. Zhou, and Y.-C. Cheng. 1992. Biochemical pharmacology of (+) and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 267:22414-22420.
5. Chen, C.-H., M. Vazquez-Padua, and Y.-C. Cheng. 1991. The effect of anti-HIV nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39:625-628.
6. Chen, C. H., and Y.-C. Cheng. 1992. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2′,3′-dideoxycytidine. J. Biol. Chem. 267:2856-2859.
7. Cheng, Y.-C., B. Domin, and L.-S. Lee. 1977. Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients. Biochim. Biophys. Acta 481:481-492.
8. Coates, J. A. V., N. Cammack, H. J. Jenkinson, I. M. Mutton, B. A. Pearson, R. Storer, J. M. Cameron, and C. R. Penn. 1992. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob. Agents Chemother. 36:202-205.
9. Collier, A. C., R. W. Coombs, D. A. Schoenfeld, R. L. Bassett, J. Timpone, A. Baruch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, H. M. Friedman, T. C. Merigan, R. C. Reichman, C. Hooper, and L. Corey. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N. Engl. J. Med. 334:1011-1017.
10. Delta Coordinating Committee. 1996. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348: 283-291.
11. + cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
12. Eron, J. J., Jr., V. A. Johnson, D. P. Merrill, T.-C. Chou, and M. S. Hirsch. 1992. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycitidine in vitro. Antimicrob. Agents Chemother. 36:1559-1562.
13. Faraj, A., L. A. Agrofoglio, J. K. Wakefield, S. McPherson, C. D. Morrow, G. Gosselin, C. Mathes, J.-L. Imbach, R. F. Schinazi, and J. P. Sommadossi. 1994. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5′-triphosphate β enantiomers of cytidine analogs. Antimicrob. Agents Chemother. 38:2300-2305.
14. Furman, P. A., M. Davis, D. C. Liotta, M. Paff, L. W. Frick, D. J. Nelson, R. E. Dornsife, J. A. Wurster, L. J. Wilson, J. A. Fyfe, J. W. Tuttle, W. H. Miller, L. Condreay, D. R. Averett, R. F. Schinazi, and G. R. Painter. 1992. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:2686-2692.
15. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
16. Gosselin, G., R. F. Schinazi, J.-P. Sommadossi, C. Mathé, M.-C. Bergogne, A.-M. Aubertin, A. Kirn, and J.-L. Imbach. 1994. Anti-human immunodeficiency virus activities of the β-L enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob. Agents Chemother. 38:1292-1297.
17. Grove K. L., X. Guo, S.-H. Liu, C.-K. Chu, and Y.-C. Cheng. 1995. Anticancer activity of β-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L-configuration. Cancer Res. 55:3008-3011.
18. Hammer, S. M., D. A. Katzenstein, M. D. Hughes, H. Gundacker, R. T. Schooley, R. H. Haubrich, W. K. Henry, M. M. Lederman, J. P. Phair, M. Niu, M. S. Hirsch, and T. C. Merigan. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N. Engl. J. Med. 335:1081-1090.
19. Johnson, V. A., D. P. Merrill, J. A. Videler, T.-C. Chou, R. E. Byington, J. J. Eron, R. T. D'Aquila, and M. S. Hirsch. 1991. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-α A inhibit replication of zidovudine-resistant human immunodeficiency virus type I synergistically in vitro. J. Infect. Dis. 164:646-655.
20. Kim, K. O., R. F. Schinazi, K. Shanmuganathan, L. S. Jeong, J. W. Beach, S. Nampalli, D. L. Cannon, and C. K. Chu. 1993. L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. J. Med. Chem. 36:519-528.
21. Kukhanova, M., S.-H. Liu, D. Mozzherin, T.-S. Lin, C.-K. Chu, and Y.-C. Cheng. 1995. L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases: implications for the mechanism of toxicity. J. Biol. Chem. 270:23055-23059.
22. Kukhanova, M., X. Li, S. H. Chen, I. King, T. Doyle, W. Prusoff, and Y. C. Cheng. Interaction of β-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine 5′-triphosphate with HIV-1 reverse transcriptase and human DNA polymerases: implications for HIV drug design. Mol. Pharmacol., in press.
23. Larder, B. A., B. Chesebro, and D. D. Richman. 1990. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob. Agents Chemother. 34:436-441.
24. Lee, L.-S., and Y.-C. Cheng. 1976. Human deoxythymidine kinase. I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia. J. Biol. Chem. 251: 2600-2604.
25. Lin, T. S., M. Z. Luo, M. C. Liu, S. B. Pai, G. E. Dutschman, and Y. C. Cheng. 1994. Antiviral activity of β-L(-)-2′,3′-dideoxy-5-fluorocytidine (L(-)FddC) and β-L(-)-2′,3′-dideoxycytidine (L(-)ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem. Pharmacol. 47:171-174.
26. Lin, T. S., M. Z. Luo, M. C. Liu, S. B. Pai, G. E. Dutschman, and Y. C. Cheng. 1994. Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). J. Med. Chem. 37:798-803.
27. Lin, T. S., M. Z. Luo, C. C. Liu, Y. L. Zhu, E. Gullen, G. E. Dutschman, and Y. C. Cheng. 1995. Synthesis of a series of purine 2′,3′-dideoxy-L-nucleoside analogues as potential antiviral agents. Nucleosides Nucleotides 14:1759-1783.
28. Lin, T.-S., M.-Z. Luo, M.-C. Liu, Y.-L. Zhu, E. Gullen, G. E. Dutschman, and Y.-C. Cheng. 1996. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-dideoxy-2′,3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 39:1757-1759.
29. Martin, L. T., A. Faraj, R. F. Schinazi, G. Gosselin, C. Mathe, J.-L. Imbach, and J.-P. Sommadossi. 1997. Effect of stereoisomerism on the cellular pharmacology of β-enantiomers of cytidine analogs in Hep-G2 cells. Biochem. Pharmacol. 53:75-87.
30. Mellors, J. W., G. E. Dutschman, G. J. Im, E. Tramontano, S. R. Winkler, and Y.-C. Cheng. 1992. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:446-451.
31. Merrill, D. P., M. Moonis, T.-C. Hou, and M. S. Hirsch. 1996. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J. Infect. Dis. 173:355-364.
32. Parker, W., and Y.-C. Cheng. 1994. Mitochondrial toxicity of antiviral nucleoside analogs. J. NIH Res. 6:57-61.
33. Parker, W. B., S. C. Shaddix, B. J. Bowdon, L. M. Rose, R. Vince, W. M. Shannon, and L. L. Bennett, Jr. 1993. Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects of cellular metabolism. Antimicrob. Agents Chemother. 37:1004-1009.
34. Schinazi, R. F., A. McMillan, D. Cannon, R. Mathis, R. M. Lloyd, A. Peck, J.-P. Sommadossi, M. St. Clair, J. Wilson, P. A. Furman, G. Painter, W.-B. Choi, and D. C. Liotta. 1992. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:2423-2431.
35. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
36. Skalski, V., S.-H. Liu, and Y.-C. Cheng. 1995. Removal of anti-human immunodeficiency virus 2′,3′-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3′-5′ exonuclease. Biochem. Pharmacol. 50:815-821.
37. Sommadossi, J. P. 1993. Nucleoside analogs: similarities and differences. Clin. Infect. Dis. 16:S7-S15.
38. Staszewski, S., C. Loveday, J. J. Picazo, P. Dellarnonica, P. Skinhoj, M. A. Johnson, S. A. Danner, P. R. Harrigan, A. M. Hill, L. Verity, and H. McDade. 1996. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 276:111-117.
39. St. Clair, M., K. N. Pennington, J. Rooney, and D. W. Barry. 1995. Rapid screening of antiretroviral combinations. J. Acquired Immune Defic. Syndr. 10(Suppl. 1):S24-S27.
40. Townsend, A., J. M. LeClerc, G. E. Dutschman, D. Cooney, and Y. C. Cheng. 1985. Metabolism of 1-β-D-arabinofuranosyl-5-azacytosine and incorporation into DNA of human T-lymphoblastic cells (Molt-4). Cancer Res. 45: 3522-3528.
41. Van Draanen, N. A., M. Tisdale, N. R. Parry, R. Jansen, R. E. Dornsife, J. V. Tuttle, D. R. Averett, and G. W. Koszalka. 1994. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob. Agents Chemother. 38:868-871.
42. White, E. L., W. B. Parker, L. J. Ross, and W. M. Shannon. 1993. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogues. Antivir. Res. 22:295-308.
43. Zhu, Y.-L., G. E. Dutschman, S.-H. Liu, E. G. Bridges, and Y.-C. Cheng. 1998. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L(-)-5- fluorocytidine. Antimicrob. Agents Chemother. 42:1805-1810.
44. Zhu, Y.-L., S. B. Pai, S.-H. Liu, K. L. Grove, B. C. N. M. Jones, C. Simons, J. Zemlicka, and Y.-C. Cheng. 1997. Inhibition of replication of hepatitis B virus by cytallene in vitro. Antimicrob. Agents Chemother. 41:1755-1760.